Sign up USA
Proactive Investors - Run By Investors For Investors

AbbVie's revenue miss clouds strong Humira US sales

AbbVie Inc shares were lower on Friday after the pharma reported quarterly adjusted revenue that missed analysts' estimates as weaker-than-expected sales of its hepatitis C treatment and cancer therapy overshadowed strong US demand for its flagship drug, Humira
AbbVie's revenue miss clouds strong Humira US sales
Is AbbVie's test tube half full or half empty?

Abbvie Inc (NYSE:ABBV) shares were lower on Friday after the pharma reported quarterly adjusted revenue that missed analysts' estimates as weaker-than-expected sales of its hepatitis C treatment and cancer therapy overshadowed strong US demand for its flagship drug, Humira.

The company's shares were down 2.4% at $59.80 on Friday, erasing more than $2.5bn of its market value.

AbbVie has sharpened its focus on oncology to reduce its reliance on Humira. The company bought Pharmacyclics and its half-ownership of the leukemia drug, Imbruvica, for $21bn in 2015.

Sales of the drug, which is also sold by Johnson & Johnson (NYSE:JNJ), fell short of fourth-quarter expectations, partly due to an inventory issue.

However, AbbVie said it expects 2017 Imbruvica sales of $2.4bn, up from $1.83bn last year.

Sales of Abbvie's hepatitis C treatment, Vikiera Pak, also missed estimates, hurt by competition from Gilead Sciences Inc (NASDAQ:GILD) and Merck & Co Inc (NYSE:MRK).

The company forecast full-year Vikiera sales of $1bn, below the $1.52bn the drug yielded last year.

The sales expectations come when investors are already jittery about looming biosimilar competition for Humira, the world's top-selling drug as well as uncertainties around the sector if US President Donald Trump carries out his threat to stamp on high-rise drug prices.



Register here to be notified of future ABBV Company articles
View full ABBV profile View Profile

Abbvie Timeline

Related Articles

1-Operation.jpg
January 18 2017
Deltex’s overseas sales are booming but its previously dominant NHS revenues are dropping off
Microbes
April 16 2017
Stephen O’Hara created Opti as a company all by himself in 2012 as a business focused on the rapidly growing microbiome space, which harnesses the positive benefits of microbes that live on the human body
Stem Cells
March 30 2017
WideCells is aiming to be a major supporting player through its development of a stem cell storage business and, having only listed in London last July, its newsflow so far looks to be pointing the way
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use